Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study

医学 贝伐单抗 彭布罗利珠单抗 肿瘤科 化疗 危险系数 实体瘤疗效评价标准 内科学 外科 癌症 进行性疾病 免疫疗法 置信区间
作者
D. Lorusso,Nicoletta Colombo,Coraline Dubot,M.V. Cáceres,Kazuki Hasegawa,Ronnie Shapira‐Frommer,Pamela Salman,Eduardo Yáñez,Mahmut Gümüş,Mivael Olivera,Vanessa Samouëlian,Vincent Castonguay,A. Arkhipov,Ka Wan Li,S. Toker,C. Tekin,Krishnansu S. Tewari,B.J. Monk
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:36 (1): 65-75 被引量:47
标识
DOI:10.1016/j.annonc.2024.10.002
摘要

HIGHLIGHTS•This exploratory analysis of KEYNOTE-826 examined treatment outcomes in patient subgroups defined by bevacizumab (beva) use•Pembrolizumab+chemotherapy improved progression-free survival and overall survival vs placebo+chemotherapy in all subgroups•The safety profile of pembrolizumab+chemotherapy±beva was manageable•Results support use of pembrolizumab+chemotherapy±beva for persistent, recurrent, or metastatic cervical cancerABSTRACTBackgroundIn KEYNOTE-826 (NCT03635567), pembrolizumab plus chemotherapy (± bevacizumab) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with persistent, recurrent, or metastatic cervical cancer. This exploratory analysis examined outcomes in patient subgroups defined by bevacizumab use.Patients and methodsEligible adult patients had persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix not previously treated with chemotherapy and not amenable to curative treatment; measurable disease per RECIST v1.1; and an Eastern Cooperative Oncology Group performance status ≤1. Patients were randomized 1:1 to pembrolizumab 200 mg every 3 weeks or placebo for up to 35 cycles plus chemotherapy (± bevacizumab 15 mg/kg). Dual primary endpoints were OS and PFS per RECIST v1.1 by investigator assessment. Outcomes were assessed in subgroups defined by bevacizumab use. Hazard ratios (HRs) and 95% CIs were based on a stratified Cox regression model.Results617 patients were randomized (pembrolizumab arm, n=308 [63.6% with bevacizumab]; placebo arm, n=309 [62.5% with bevacizumab]). The most common reason for bevacizumab exclusion was medical contraindication (75.9%). Among patients who received bevacizumab, HRs (95% CIs) for PFS favored the pembrolizumab arm in the PD-L1 combined positive score (CPS) ≥1 (0.56 [0.43−0.73]) and all-comer (0.57 [0.45−0.73]) populations; OS results were 0.60 (0.45−0.79) and 0.61 (0.47−0.80), respectively. Among patients who did not receive bevacizumab, HRs (95% CIs) for PFS also favored the pembrolizumab arm in the PD-L1 CPS≥1 (0.61 [0.44−0.85]) and all-comer (0.69 [0.50−0.94]) populations; OS results were 0.61 (0.44−0.85) and 0.67 (0.49−0.91), respectively. Among patients who received bevacizumab, grade ≥3 treatment-related adverse events occurred in 74.0% of patients in the pembrolizumab arm and 66.8% in the placebo arm.ConclusionPembrolizumab plus chemotherapy prolonged PFS and OS and had manageable safety compared with placebo plus chemotherapy in patient subgroups defined by bevacizumab use.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
cc发布了新的文献求助10
2秒前
alwayslifted发布了新的文献求助10
3秒前
5秒前
5秒前
希望天下0贩的0的应助被PDIF-CN2采纳,获得10
6秒前
小李完成签到 ,获得积分10
6秒前
脑洞疼的应助被hbety采纳,获得10
7秒前
怀夕完成签到,获得积分10
7秒前
王号完成签到,获得积分20
9秒前
负责风华发布了新的文献求助20
9秒前
简荼完成签到,获得积分10
9秒前
10秒前
科研通AI2S的应助被taozhanhua采纳,获得10
10秒前
lmhhh发布了新的文献求助10
10秒前
6yy发布了新的文献求助30
11秒前
小马甲的应助被陶醉平灵采纳,获得10
12秒前
12秒前
13秒前
天天快乐的应助被简荼采纳,获得10
13秒前
14秒前
酥SUSU完成签到,获得积分10
15秒前
15秒前
Oasis完成签到,获得积分10
16秒前
无极微光的应助被王号采纳,获得20
16秒前
小包谷完成签到,获得积分10
17秒前
Bruce_Wayne发布了新的文献求助10
17秒前
17秒前
18秒前
挚友发布了新的文献求助10
18秒前
18秒前
不灵0发布了新的文献求助30
19秒前
天天向上的应助被lmhhh采纳,获得30
19秒前
20秒前
李健的小迷弟的应助被youknowdcf采纳,获得10
20秒前
Jing发布了新的文献求助10
21秒前
哎呦呦仔发布了新的文献求助10
22秒前
wyitong2024完成签到 ,获得积分10
22秒前
molec发布了新的文献求助10
23秒前
赘婿的应助被zhouyang采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177667
求助须知:如何正确求助?哪些是违规求助? 9568537
关于积分的说明 21799700
捐赠科研通 7772307
什么是DOI,文献DOI怎么找? 3432429
关于科研通互助平台的介绍 2556651
邀请新用户注册赠送积分活动 2478011